Biodiversity provides critical support for drug discovery and the availability of medicinal resources. A significant proportion of drugs are derived, directly or indirectly, from biological sources: at least 50% of the pharmaceutical compounds on the US market are derived from plants, animals, and micro-organisms, while about 80% of the world population depends on medicines from nature (used in either modern or traditional medical practice) for primary healthcare. Only a tiny fraction of wild species has been investigated for medical potential. Biodiversity has been critical to advances throughout the field of bionics. Evidence from market analysis and biodiversity science indicates that the decline in output from the pharmaceutical sector since the mid-1980s can be attributed to a move away from natural product exploration ("bioprospecting") in favor of genomics and synthetic chemistry, indeed claims about the value of undiscovered pharmaceuticals may not provide enough incentive for companies in free markets to search for them because of the high cost of development; meanwhile, natural products have a long history of supporting significant economic and health innovation. Marine ecosystems are particularly important, although inappropriate bioprospecting can increase biodiversity loss, as well as violating the laws of the communities and states from which the resources are taken.

What provides critical support for drug discovery and the availability of medicinal resources?